Circulating endothelial cells in patients with septic shock.
M Mutunga, B Fulton, R Bullock...
https://pubmed.ncbi.nlm.nih.gov/11208646/Actively Recruiting
Led by SeaStar Medical · Updated on 2026-10-22
339
Participants Needed
36
Research Sites
26 weeks
Total Duration
Researchers are evaluating whether up to ten consecutive 24-hour treatments with the Selective Cytopheretic Device SCD can improve survival in patients with Acute Kidney Injury AKI who need continuous kidney replacement therapy CKRT. The study compares the use of SCD plus standard CKRT to CKRT alone to see if it reduces the need for long-term dialysis. This pivotal randomized controlled trial will include about 339 patients in intensive care units across 30 US sites. Participants will be assigned to one of two groups one group will receive up to ten 24-hour treatments using the SCD connected to their existing CKRT circuit along with standard care, while the other group will receive standard CKRT care alone. The SCD is a device designed to modulate inflammation by binding activated white blood cells during CKRT using regional citrate anticoagulation. Treatments occur sequentially over the study period. During the study, participants will be monitored for survival and dialysis dependency at 90 days, as well as dialysis dependence at 1 year, ICU-free days within the first 28 days, and mortality at 28 days. The trial includes assessments related to kidney function and patient outcomes over time. Participation involves regular monitoring during ICU care, with results informing the safety and effectiveness of adding SCD therapy to standard CKRT. The study is expected to continue until June 2027.
CONDITIONS
Neutrophil and Monocyte Deactivation Via the SeLective CytopheretIc Device - A Randomized Clinical Trial in Acute Kidney Injury
M
Mohamed Zidan, MD
K
Kevin K Chung, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
SeaStar Medical
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | SCD + CKRT | CKRT alone | Standard CKRT (guideline‑based) |
|---|---|---|---|
| What it is | An investigational extracorporeal cartridge (Selective Cytopheretic Device) added to the CKRT circuit to modulate inflammation via leukocyte binding under citrate anticoagulation. | Standard continuous kidney replacement therapy alone as provided in the trial comparator arm. | Continuous kidney replacement therapy as per current critical care guidelines for managing AKI in critically ill patients. |
| Role in trial | Investigational treatment arm including SCD added to CKRT. | Control arm receiving CKRT alone as standard care. | Represents guideline‑based practice outside the trial. |
| Primary use | Modulate leukocyte‑mediated inflammation in AKI patients on CKRT in ICU. | Support kidney function and manage fluid and solute balance in AKI requiring CKRT. | Provide continuous renal replacement therapy to critically ill AKI patients according to guideline‑recommended modality and dosing. |
| How it is given or performed | SCD cartridge is placed in series with CKRT hemofilter; regional citrate anticoagulation maintains low ionized calcium to enable leukocyte binding. | Standard CKRT delivered via commercial hemofilter using institution‑defined protocols and anticoagulation. | CKRT regimen tailored per clinical guidelines, including modality choice, anticoagulation strategy, and dosing targets. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 10 days
Participants receive up to ten sequential 24-hour treatments with the Selective Cytopheretic Device connected to their continuous kidney replacement therapy circuit, or standard therapy alone as assigned.
Daily treatments for up to 10 days
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
M Mutunga, B Fulton, R Bullock...
https://pubmed.ncbi.nlm.nih.gov/11208646/Feng Ding, Alexander S Yevzlin, Z Y Xu...
https://pubmed.ncbi.nlm.nih.gov/21317636/VA/NIH Acute Renal Failure Trial Network, Paul M Palevsky, Jane Hongyuan Zhang...
https://pubmed.ncbi.nlm.nih.gov/18492867/ARDS Definition Task Force, V Marco Ranieri, Gordon D Rubenfeld...
https://pubmed.ncbi.nlm.nih.gov/22797452/Lenar T Yessayan, Javier A Neyra, Angela J Westover...
https://pubmed.ncbi.nlm.nih.gov/35620768/Stuart L Goldstein, David J Askenazi, Rajit K Basu...
https://pubmed.ncbi.nlm.nih.gov/33732992/Nele Van Den Noortgate, Veerle Mouton, Caroline Lamot...
https://pubmed.ncbi.nlm.nih.gov/12637642/Laura Evans, Andrew Rhodes, Waleed Alhazzani...
https://pubmed.ncbi.nlm.nih.gov/34605781/J W Hall, W J Johnson, F T Maher...
https://pubmed.ncbi.nlm.nih.gov/5506002/F Liaño, E Junco, J Pascual...
https://pubmed.ncbi.nlm.nih.gov/9580541/SeaStar Medical
Lead Sponsor